Trial Profile
A Phase 1, Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Nanoparticle Vaccine, With or Without Matrix-M Adjuvant, in Healthy Subjects ≥18 to <50 Years of Age
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Nov 2021
Price :
$35
*
At a glance
- Drugs EBOV GP vaccine (Primary) ; Matrix M
- Indications Ebola virus infections
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Novavax
- 11 Oct 2019 Results published in the Journal of Infectious Diseases
- 20 Sep 2016 Status changed from active, no longer recruiting to completed.
- 08 Jun 2016 Planned End Date changed from 1 Apr 2016 to 1 Jun 2016.